1. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2–EED Interaction
   Daohai Du et al, 2021, Journal of Medicinal Chemistry CrossRef
2. Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer
   Qian-Qian Wang et al, 2022, World Journal of Clinical Cases CrossRef
3. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy
   Natsuki Saigusa et al, 2022, Frontiers in Oncology CrossRef
4. EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment
   Chen Li et al, 2022, Frontiers in Immunology CrossRef
5. Genetic Impairments of PRC2 Activity in Oncology: Problems and Prospects
   D. A. Chetverina et al, 2021, Russian Journal of Genetics CrossRef
6. Clinicopathologic significance of protein lysine methyltransferases in cancer
   Theodore Vougiouklakis et al, 2020, Clinical Epigenetics CrossRef